Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| granulocyte colony stimulating factor (G-CSF) type substances | 5756 | 2200269-79-8 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Efbemalenograstim alfa-vuxw is a colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 16, 2023 | FDA | EVIVE BIOTECHNOLOGY |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | L03AA18 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSTIMULANTS IMMUNOSTIMULANTS Colony stimulating factors |
| FDA CS | M0004822 | Colony-Stimulating Factors |
| FDA EPC | N0000175666 | Leukocyte Growth Factor |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Febrile neutropenia caused by myelosuppressive anti-cancer drugs | indication | 409089005 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Granulocyte colony-stimulating factor receptor | Membrane receptor | BINDING AGENT | UNKNOWN | DRUG LABEL | |||||
| IgG receptor FcRn large subunit p51 | Membrane receptor | BINDING AGENT | UNKNOWN | DRUG LABEL |
| ID | Source |
|---|---|
| CHEMBL4297950 | ChEMBL_ID |
| C000731753 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4043953 | VANDF |
| C5400023 | UMLSCUI |
| CHEBI:757380 | CHEBI |
| 11068 | INN_ID |
| 42190 | MMSL |
| d10135 | MMSL |
| 5UPW5HJW3O | UNII |
| 2670630 | RXNORM |
| D11986 | KEGG_DRUG |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| RYZNEUTA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72893-016 | INJECTION | 20 mg | SUBCUTANEOUS | BLA | 26 sections |